Ticelo Injection contains nelarabine as its active constituent, classified under antineoplastic agents. It is primarily used in the treatment of certain types of blood cancers, specifically T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). This medication works by disrupting cancer cell growth, ultimately leading to their destruction. As a chemotherapy drug, it is prescribed under strict medical supervision due to its potent effects and potential side effects.

Before starting treatment, patients must be evaluated for pre-existing health conditions, including liver and kidney function, neurological status, and blood cell counts. It is not recommended for individuals with severe neurological disorders or those who have previously exhibited hypersensitivity to its components. Special caution is required for pregnant and breastfeeding women, as the drug may cause serious harm to the fetus or infant. Patients should adhere to safety measures to minimise adverse effects and ensure optimal therapeutic outcomes.

Ticelo Injection is FDA-approved for the treatment of:

1. T-cell acute lymphoblastic leukemia (T-ALL)

2. T-cell lymphoblastic lymphoma (T-LBL)

This medication belongs to the class of antimetabolites and acts by interfering with DNA synthesis within rapidly dividing cancer cells. Once inside the body, it is converted into its active form, which integrates into the DNA of malignant cells, disrupting their ability to multiply. This ultimately leads to cell death and reduces the progression of the disease. Due to its targeted mechanism, it is highly effective in treating specific blood malignancies while requiring careful monitoring to manage its associated risks.

Serious drug interactions can impact the efficacy of chemotherapy and increase the risk of adverse effects. Patients should inform their healthcare provider about all ongoing medications before starting treatment.

• Immunosuppressants (e.g., cyclosporine, tacrolimus): May heighten the risk of severe infections.

• Other chemotherapeutic agents (e.g., methotrexate): Increased risk of toxicity, including severe bone marrow suppression.

• CNS depressants (e.g., benzodiazepines, opioids): Potential exacerbation of neurological side effects.

• Live vaccines: Heightened risk of infections due to immunosuppression.

• Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): May impair kidney function and alter drug elimination.

• Store at a controlled temperature (20-25°C) away from direct sunlight and moisture.

• If a dose is missed, consult a healthcare professional before making up for it.

• In case of overdose, seek immediate medical attention due to the risk of severe toxicity.

Ticelo Injection is available as an intravenous (IV) infusion and is administered by a healthcare professional in a clinical setting. The dosage is carefully determined based on the patient’s body surface area, overall health status, and response to treatment. It is typically given in cycles, allowing for adequate intervals between doses to enable the body to recover and minimise potential side effects.

Common Side Effects:

• Fatigue

• Nausea and vomiting

• Decreased appetite

• Fever

• Muscle weakness

Serious Side Effects:

• Severe bone marrow suppression

• Peripheral neuropathy (tingling, numbness, or weakness in limbs)

• Severe infections due to low white blood cell count

• Cognitive and coordination impairments

• Seizures (in rare cases)

• Maintain regular follow-up appointments to monitor blood counts and overall health during treatment.

• Report any neurological symptoms such as confusion or muscle weakness to a healthcare provider immediately.

• Ensure adequate hydration to help reduce the risk of kidney-related side effects.

• Since the treatment can suppress immune function, avoid crowded places and limit exposure to potential infections.

• Incorporate supportive therapies and lifestyle modifications to improve tolerance and enhance overall treatment outcomes.